• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      The Swedish Council on Health Technology Assessment (SBU)
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25514 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     Canada’s Drug Agency (CDA-AMC) Teleoptometry for eye exams
2026     Canada’s Drug Agency (CDA-AMC) Antiviral drugs for the treatment of suspected or confirmed influenza A or influenza B
2026     Canada’s Drug Agency (CDA-AMC) Cryoneurolysis for patients undergoing total knee arthroplasty
2026     Canada’s Drug Agency (CDA-AMC) Cryoneurolysis for patients undergoing surgical stabilization of rib fractures
2026     Canada’s Drug Agency (CDA-AMC) Dosing of immune checkpoint inhibitors
2026     Canada’s Drug Agency (CDA-AMC) Nabilone for the management of behavioral and psychological symptoms of dementia
2026     Canada’s Drug Agency (CDA-AMC) Teleaudiology for hearing assessments
2026     Canada’s Drug Agency (CDA-AMC) Longevity of relined or rebased dentures
2026     Canada’s Drug Agency (CDA-AMC) Dextrose prolotherapy for musculoskeletal conditions
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Hypertension – antihypertensive medication adjustment and monitoring]
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Tirzepatide (Zepbound)]
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Donanemab (Kisunla)]
2026     Basque Office for Health Technology Assessment (OSTEBA) [Home self-management of oral anticoagulation therapy with vitamin K antagonists: evaluation of acceptability and cost-effectiveness]
2026     Basque Office for Health Technology Assessment (OSTEBA) [Active piezoelectric bone conduction hearing implant]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Single-port endoluminal robotic system for endoscopic submucosal dissection in patients with superficial colorectal lesions]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Tumor biomarkers related to the management of advanced neuroendocrine tumors]
2026     Canada’s Drug Agency (CDA-AMC) Ferric derisomaltose for heart failure and iron deficiency
2026     Canada’s Drug Agency (CDA-AMC) Botulinum toxin A product comparison for upper limb spasticity, lower limb spasticity, and cervical dystonia
2026     Canada’s Drug Agency (CDA-AMC) Cost-effectiveness of antiviral drugs to prevent or treat influenza A, influenza B, or zoonotic influenza
2026     Canada’s Drug Agency (CDA-AMC) Antiviral drugs for post-exposure prophylaxis against influenza A or influenza B
2026     Scottish Health Technologies Group (SHTG) National framework for evaluating the role of Surgical Care Practitioners (SCPs) in Scotland
2026     Scottish Health Technologies Group (SHTG) Pre-hospital extracorporeal cardiopulmonary resuscitation (ECPR) for adult patients experiencing refractory out-of-hospital cardiac arrest (OHCA)
2026     Scottish Health Technologies Group (SHTG) Computed tomography coronary angiography (CTCA) and CT fractional flow reserve (CT-FFR) for investigation of patients with stable chest pain
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Digital self-care solutions for non-specific lower back pain]
2026     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Benefits and risks of using smart infusion pumps for parenteral drug administration]
2026     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Bioimpedance phase angle analysis as prognostic in patients with palliative care needs in chronic non-oncological diseases]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Comparison of the Edgington method with standard procedures for fixed-effect meta-analyses in a scenario with 2 studies]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Thresholds for responder analyses of complex scales in benefit assessments – the 15% approach]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Second addendum to Project A26-11]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inotuzumab ozogamicin (relapsed/refractory ALL, children >= 1 year ) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pretomanid (tuberculosis) – Assessment according to §35a (para. 1c) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tovorafenib (low-grade glioma in paediatric patients) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belumosudil (chronic graft-versus-host disease in adults and children 12 years and older) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; adjuvant treatment) –Addendum to Project A26-17]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Colchicine (prophylaxis of ischaemic cardiovascular events after myocardial infarction) – Addendum to Project A26-16]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivosidenib (acute myeloid leukaemia) – Addendum to Project A26-19]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Addendum to Project A26-11]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Clesrovimab (secondary prevention of RSV lower respiratory tract disease) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Deucravacitinib (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab/relatlimab (melanoma) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aficamten (obstructive hypertrophic cardiomyopathy) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Clascoterone (acne vulgaris) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (B-ALL, newly diagnosed, consolidation therapy) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (B-ALL, high-risk first relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (B-ALL, 1st and 2nd complete remission) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (B-ALL, refractory or relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (B-ALL, relapsed or refractory) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Marstacimab (haemophilia B, with factor IX inhibitors) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Marstacimab (haemophilia A, with factor VIII inhibitors) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (CML, T315I mutation, previously treated) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zolbetuximab (gastric or gastro-oesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (chronic spontaneous urticaria in adults and adolescents 12 years and above) – Benefit assessment according to §35a]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (chronic spontaneous urticaria in children >= 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olipudase alfa (acid sphingomyelinase deficiency) – Benefit assessment according to §35a Social Code Book V]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (heart failure with LVEF ≥ 40%) – Benefit assessment according to §35a Social Code Book V]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Cell and gene therapies: reflections for optimal deployment]
2026     National Institute for Health and Care Excellence (NICE) Ex-situ machine perfusion devices to preserve deceased donor livers for transplantation. NICE HealthTech guidance 780
2026     National Institute for Health and Care Excellence (NICE) Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction. NICE technology appraisal guidance 1182
2026     National Institute for Health and Care Excellence (NICE) Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 1185
2026     National Institute for Health and Care Excellence (NICE) Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma. NICE technology appraisal guidance 1184
2026     National Institute for Health and Care Excellence (NICE) Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over. NICE technology appraisal guidance 1183
2026     National Institute for Health and Care Excellence (NICE) Rilzabrutinib for treating persistent or chronic immune thrombocytopenia (terminated evaluation). NICE technology appraisal guidance 1187
2026     National Institute for Health and Care Excellence (NICE) Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation). NICE technology appraisal guidance 1186
2026     National Institute for Health and Care Excellence (NICE) Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over (terminated evaluation). NICE technology appraisal guidance 1188
2026     National Institute for Health and Care Excellence (NICE) Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1189
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, efficacy, clinical effectiveness, cost-effectiveness and budgetary impact of routine neonatal screening for Pompe disease using tandem mass spectrometry on dried heel-prick blood spots]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Cellulitis in adults and children: identification, diagnosis, optimal use of antibiotics, and measures to prevent complications or recurrences]
2026     NIHR Health Technology Assessment programme Decompressive craniectomy versus craniotomy for patients undergoing surgical evacuation of an acute subdural hematoma: RESCUE-ASDH RCT and cost effectiveness
2026     NIHR Health Services and Delivery Research programme Individual Participant Data Meta-Analysis (IPDMA) of long-term COVID-19 outcomes in a systematic review-informed, international, multidisciplinary database
2026     NIHR Health Technology Assessment programme Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study
2026     NIHR Health Technology Assessment programme Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome – a systematic review and economic evaluation
2026     Scottish Health Technologies Group (SHTG) Surgical Care Practitioners
2026     Scottish Health Technologies Group (SHTG) Surface guided radiation therapy
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Digital self-care solutions for depressive and anxiety disorders]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Digital self-care solutions for chronic obstructive pulmonary disease]
2026     Penn Medicine Center for Evidence-based Practice (CEP) Clevidipine for patients with acute intracerebral hemorrhage (ICH)
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Liquid biopsy in oncology: expanding its use in Quebec]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Molecular profiling of circulating tumor DNA from a liquid biopsy for therapeutic decision-making in breast cancer patients]
2026     Canary Health Service [Update of the cost-effectiveness of routine childhood vaccination against invasive meningococcal disease caused by serogroups A, C, W and Y in children aged 4 and 12 months]
2026     Canary Health Service [Robotic surgical system for minimally invasive total hysterectomy with or without salpingoophorectomy for benign disease or prophylactic surgery]
2026     Canary Health Service [Ultrasound-guided percutaneous treatment of carpal tunnel syndrome and stenosing tenosynovitis]
2026     Canary Health Service [Update on the cost-effectiveness of routine childhood vaccination against hepatitis A]
2026     Canary Health Service [Stepped care model in mental health]
2026     Canary Health Service [Wearable telemonitoring systems for fall-risk assessment and fall detection in adults aged 65 years and older]
2026     Canary Health Service [Electroconvulsive therapy in severe or treatment-resistant depression]
2026     Canary Health Service [Strategies for the efficient management of waiting lists and improved resource optimisation]
2026     Canary Health Service [Repetitive transcranial magnetic stimulation for motor, linguistic and cognitive sequelae of stroke]
2026     Canary Health Service [Protocol for the early diagnosis of celiac disease. Update]
2026     Health Information and Quality Authority (HIQA) Protocol for an analysis of tobacco affordability in Ireland
2026     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of the addition of congenital adrenal hyperplasia to the National Newborn Bloodspot Screening Programme
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Molecular profiling of circulating tumor DNA from a liquid biopsy for therapeutic decision-making in patients with prostate cancer]
2026     NIHR Health Technology Assessment programme Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model
2026     NIHR Health Services and Delivery Research programme Extra care housing in the UK: a scoping review
2026     NIHR Health Services and Delivery Research programme Exploring and improving resuscitation decisions in out of hospital cardiac arrest: synopsis of the PROTECTeD mixed-method study
2026     NIHR Health Technology Assessment programme Development and evaluation of the electronic frailty index+ (eFI+) tool for older people: prognostic prediction modelling with integrated decision curve and health economic analysis
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Overview of the use of potentially inappropriate medications among community-dwelling individuals living with major neurocognitive disorders in Québec between 2014 and 2024]
2026     NIHR Health Technology Assessment programme Interventions to reduce pain at dressing change of chronic wounds: a mixed-methods systematic review
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Immunoassay for free blood valproic acid]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Companion guide for the evaluation of the National Policy for Caregivers]
2026     National Institute for Health and Care Excellence (NICE) Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor. NICE technology appraisal guidance 1173